Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 13/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | LDHB | P07195 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23012663 | 0.83 | ALKBH2 (0.46) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL29507151 | 0.83 | ALKBH2 (0.46) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL31448239 | 0.83 | PIK3CD (0.47) | ADORA2APIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL31448269 | 0.79 | ADORA2A (0.46) | ADORA2APIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL23022201 | 0.79 | ADORA2A (0.46) | ADORA2APIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL23022254 | 0.78 | ADORA2A (0.40) | ADORA2APIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL31448116 | 0.74 | CHEK1 (0.56) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL31448254 | 0.74 | PIK3CD (0.50) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL31448229 | 0.74 | HDAC6 (0.41) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL23012226 | 0.74 | ADORA2A (0.48) | ADORA2APIK3CDPIK3R1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114341127-B | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-116082307-A | HPK1 inhibitor and application thereof in medicine | 贝达药业股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-09-15 | — | — | US | disclosed |
| CN-114341127-A | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021032148-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | MAPKAPK5, STK25, STK35 | ADORA2A 3042/4885PIK3CD 1894/4885PIK3R1 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.